Algorae Pharmaceuticals Ltd Wins NSW Health Public Hospital Supply Contract
Algorae secures NSW Health public hospital supply contract
Algorae Pharmaceuticals (ASX: 1AI) has been awarded a public hospital supply contract with NSW Health following a competitive tender process. The contract was awarded to Algorae, supported by AlgoraeRx, the Company’s wholly owned commercial division.
The agreement carries an initial three-year term, with two optional one-year extensions (3+1+1 years). Onboarding and rollout are already underway, with first supply expected in Q4 2026.
Contract scope, pricing and volumes are confidential under the agreement, and the Company is unable to quantify the financial impact at this time. Revenue from the agreement will be recognised within the Company’s total product revenue.
For investors, the award provides access to one of Australia’s largest public healthcare procurement networks, strengthening the near-term commercial foundation of the Company’s dual-track strategy.
When big ASX news breaks, our subscribers know first
Inside the tender award and rollout timeline
Algorae was selected as a supplier under the NSW Health public hospital supply contract following a competitive tender process. Onboarding and rollout are already in progress.
Key contract facts:
- Counterparty: NSW Health
- Initial term: 3 years
- Optional extensions: 2 × 1-year (3+1+1)
- First supply expected: Q4 2026
- Pricing/volumes: confidential
The Company has stated it will make further disclosures “if and when the information becomes capable of disclosure,” in line with its continuous disclosure obligations.
Vishal Shah, Managing Director and Chief Commercial Officer of AlgoraeRx
“Securing a place on a NSW Health supply contract is a major milestone for AlgoraeRx. It validates the strength of our commercial capabilities and provides access to one of Australia’s largest public healthcare procurement networks.”
Understanding Algorae’s dual-track strategy
Algorae operates two complementary arms, combining AI-driven drug discovery with pharmaceutical commercialisation. Understanding how these tracks fit together provides useful context for the latest award.
The first track is AlgoraeOS, a proprietary AI platform that applies machine learning and deep neural networks to predict synergistic drug combinations. The platform was developed in collaboration with the UNSW AI Institute, with support from CSIRO Data61, and its predictions have been independently validated by the Peter MacCallum Cancer Centre. Its pipeline spans oncology, neurodegenerative and other complex diseases.
The second Peter MacCallum collaboration, screening 24 AI-predicted drug combination candidates across four cancer cell lines, represents the longer-term pipeline work running in parallel to the near-term commercial rollout that the NSW Health contract now anchors.
The second track is AlgoraeRx, the wholly owned commercial division. It brings specialty and generic medicines to market across Australia and New Zealand under distribution and supply partnerships.
The Zydus Lifesciences partnership, which grants Algorae exclusive distribution rights across injectable, oral and specialty pharmaceutical products in hospital and community care channels, further illustrates how AlgoraeRx has been assembling a multi-product supply base ahead of revenue recognition.
For investors, the AlgoraeRx revenue base complements the longer-term discovery pipeline. The NSW Health contract reinforces that near-term revenue foundation.
| Division | Focus | Key Backing/Partners | Investor Relevance |
|---|---|---|---|
| AlgoraeOS | AI drug-combination discovery | UNSW AI Institute, CSIRO Data61, Peter MacCallum validation | Long-term pipeline upside |
| AlgoraeRx | Specialty & generic medicines (AUS/NZ) | Distribution & supply partnerships | Near-term revenue base |
The next major ASX story will hit our subscribers first
What the contract means for Algorae’s growth path
The Company regards the award as strong validation of its strategy and commercial execution, positioning it for further growth. Algorae will focus on supporting rollout, meeting its obligations under the contract, and continuing to pursue further public healthcare procurement opportunities.
Future tender award updates will be provided in the Company’s quarterly activities report.
Algorae will continue to pursue further public healthcare procurement opportunities alongside this contract. With financial terms confidential, the near-term significance lies in the market access secured rather than any disclosed dollar value.
Ready to Learn More About Algorae’s NSW Health Contract Win?
Algorae Pharmaceuticals has secured a significant foothold in one of Australia’s largest public healthcare procurement networks, with first supply under the NSW Health contract expected in Q4 2026. The award anchors the near-term revenue foundation of the Company’s dual-track strategy, combining AI-driven drug discovery with active pharmaceutical commercialisation across Australia and New Zealand.
To explore Algorae’s full pipeline, commercial strategy, and investment proposition, visit the Algorae Pharmaceuticals investor centre for the latest updates direct from the Company.